Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma

NCT00501735 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.

NCT NCT00501735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00501735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma
Lead sponsor
BioCryst Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
December 31, 2011
Enrollment
144 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma (ctcl),